Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
VYLR has recovered well from its post-spinoff dip, but the tenth analyst initiation this week broke ranks with the bullish consensus, adding a note of caution just as the stock approaches the mean price target.
The Street angle is now the most interesting thing about this name. Ten firms have initiated coverage since October 2, and nine of them leaned constructive: Goldman Sachs at Buy with an $87 target, UBS at Buy with $89, Morgan Stanley Overweight at $85, and a cluster of Outperform ratings from RBC, BMO, Mizuho and Oppenheimer in the $82 to $85 range. BNP Paribas, filing its initiation on October 14, took a different view. Analyst David Symonds opened at Neutral with a $75 target, the only price target that sits below the current price of $76.94. That puts the consensus mean at $82, implying roughly 7% upside from here, but the range now stretches from $75 to $89. With the stock up 5.5% on the week and trading within a few dollars of where the most cautious analyst thinks fair value lies, the easy re-rating from spinoff discount may already be captured.
The borrow market adds little urgency to the short thesis. Availability remains extraordinarily loose at roughly 3,700%, meaning shares available to borrow dwarf those already borrowed by a factor of nearly 37. That is actually wider than the 3,400% level reported in last week's note. Cost to borrow has risen 70% over the past week to 0.60%, which sounds dramatic but remains firmly low in absolute terms. Short interest is modest and the short score has edged down from 33.5 on October 7 to 31.1 on October 12, a move that points away from building bearish conviction rather than toward it. Options positioning is mildly skewed toward calls: the put/call ratio was 0.46 on October 13, the highest of the three available daily readings but still well below a defensive level.
Factor scores tell a story of a stock that earns its hold rating rather than a screaming buy or sell. The dividend score ranks in the 97th percentile of the universe. Forward EPS growth ranks in the 73rd percentile. Value is the softer pillar: the PE ratio runs near 29.9x and EV/EBITDA near 16.2x, which has drifted higher over the past 30 days. The EV/EBITDA 30-day move of 5 points is the one valuation metric that has shifted materially, though the as-of date on the EV data extends to December 2026 and may incorporate forward estimates rather than trailing actuals. The PFAS litigation inherited from former parent CTVA remains the one overhang that none of the initiation notes has resolved.
Among the top reported holders, Charles Magro added 631,720 shares in the most recent filing, bringing his stake to 834,809 shares. Samuel Eathington, Judd O'Connor and Audrey Grimm all reported additions as well. These are smaller individual stakes, but the direction of insider-adjacent accumulation is consistent with the broader bullish initiation narrative.
The November 4 earnings event is the next hard date on the calendar: with one prior earnings reaction on record showing a 1.9% one-day decline and a 2.7% five-day drift lower, the question heading into that print is whether the valuation multiple that has expanded since the spinoff can be sustained against the first full quarterly report as a standalone agricultural products company.
See the live data behind this article on ORTEX.
Open VYLR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
